A Randomized Trial of Intensive versus Standard Blood-Pressure Control by Todd, O & Clegg, A
Corr e spondence
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 374;23 nejm.org June 9, 20162290
A Randomized Trial of Intensive versus Standard  
Blood-Pressure Control
To the Editor: Wright et al. (Nov. 26 issue)1 re-
port on the Systolic Blood Pressure Intervention 
Trial (SPRINT). By focusing on blood-pressure 
levels, rather than on specific antihypertensive 
agents, this trial follows a rich heritage of 
 government-funded, noncommercial, randomized 
trials in hypertension that address major public 
health issues. The clear differences in outcomes, 
including lower rates of death among patients 
who were randomly assigned to intensive treat-
ment than among those assigned to standard 
treatment, underscore the major impact of im-
plementing this lower blood-pressure target for 
the appropriate population.
Achievement of a difference of 15 mm Hg 
between patients who were randomly assigned 
to the intensive-treatment group (target systolic 
blood pressure <120 mm Hg) and patients who 
were randomly assigned to the standard-treat-
ment group (target <140 mm Hg) was central to 
testing the authors’ hypothesis. Their design 
article specifies that in the standard-treatment 
group, antihypertensive therapy should be with-
drawn in a patient whose systolic blood pressure 
is less than 130 mm Hg on any occasion or less 
than 135 mm Hg on two consecutive visits.2 
Since withdrawal of antihypertensive therapy in 
asymptomatic patients in whom these pressures 
are achieved is not necessarily considered to be 
standard, interpretation of the overall trial re-
sults could be affected by knowledge of how 
often, and in how many patients, this nonstan-
dard action was taken.
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To the Editor: SPRINT was terminated early 
because of a survival benefit in the intensive-
treatment group. We question the wisdom of this 
decision to truncate the trial.
In a systematic review and meta-regression 
analysis, Bassler et al.1 compared 91 truncated 
randomized, controlled trials with 424 matching 
nontruncated randomized, controlled trials ad-
dressing the same clinical questions. They found 
that the truncated trials had, on average, a 29% 
reduction in relative risk as compared with the 
nontruncated trials. The number of primary-
outcome events (which was lower in the trun-
cated trials) was a significant factor in explain-
ing differences in effect.
If we assume that SPRINT had a moderate 
overestimation of effect similar to that seen in 
the study by Bassler et al., the adjusted hazard 
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ratio with intensive treatment would increase to 
0.85 (95% confidence interval [CI], 0.73 to 1.01). 
This adjusted hazard ratio suggests either that 
intensive treatment is not significantly beneficial 
or that it is of much less benefit than the authors 
report. Before termination of a randomized, con-
trolled trial for therapeutic benefit alone, the 
risks of outcomes bias that have been established 
in truncating studies should be considered — or 
researchers will have to accept the risk of com-
mitting a type 1 error.
Benjamin Vipler, M.D.
Walter Reed National Military Medical Center 
Bethesda, MD
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To the Editor: SPRINT addresses what is per-
haps the most important question in the man-
agement of hypertension: what systolic blood-
pressure levels should be targeted in patients 
who do not have diabetes? In this trial, targeting 
a systolic blood pressure of less than 120 mm Hg, 
as compared with a systolic blood pressure of 
less than 140 mm Hg, reduced the primary com-
posite outcome by 25%.
The observed benefits, with a number needed 
to treat of 61, may redefine blood-pressure tar-
gets in clinical practice. However, clinicians 
should bear in mind that for each primary out-
come event prevented in the intensive-treatment 
group, 1.3 patients had a serious adverse event 
related to the intervention (by our calculations, 
the number needed to harm was 46); this sug-
gests the need for caution.
These results will probably reopen the discus-
sion on benefit–risk balance in the management 
of hypertension, and it would thus be of clinical 
importance to identify patient subgroups with the 
highest hazard from tight blood-pressure control 
in daily practice. The benefit–risk balance ap-
pears to be more favorable in patients who are 
older than 75 years of age. Therefore, we urge 
the SPRINT investigators to analyze the risk of 
serious adverse events related to the intervention 
according to age, baseline and achieved systolic 
and diastolic blood pressure, medication use, and 
coexisting conditions.
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Lennart Tonneijck, M.D. 
Mark M. Smits, M.D.
VU University Medical Center 
Amsterdam, the Netherlands 
ma . muskiet@ vumc . nl
No potential conflict of interest relevant to this letter was re-
ported.
DOI: 10.1056/NEJMc1602668
To the Editor: The blood-pressure measurement 
technique in SPRINT has received insufficient 
attention. The use of a programmed automated 
oscillometric blood-pressure meter, which man-
dates 5 minutes of rest followed by three readings, 
results in approximately 8 minutes of rest. This 
longer rest time alone will reduce blood pressure.1 
In addition, the requirement for “quiet rest” al-
most certainly meant that the operator would not 
have been in the room, so that blood-pressure 
reactivity would have been further reduced.2
An automated oscillometric blood-pressure 
method that is similar to that used in SPRINT 
has been shown to result in readings that are 
lower than resting manual readings by up to 
8 mm Hg in systolic blood pressure and up to 
8 mm Hg in diastolic blood pressure.3,4 As such, 
the achieved systolic blood pressure of 121 mm Hg 
and diastolic blood pressure of 69 mm Hg in the 
intensive-treatment group may be equivalent to a 
systolic blood pressure of 129 mm Hg and a 
diastolic blood pressure of 77 mm Hg if the 
blood pressure is measured manually. This is an 
important caveat for the large number of practi-
tioners who continue to rely on manual blood-
pressure measurement. Of even greater concern, 
in the standard-treatment group, the systolic blood 
pressure could have been as high as 144 mm Hg 
and the diastolic blood pressure could have been 
as high as 84 mm Hg when measured manually. 
These levels exceed current recommendations.
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To the Editor: Wright et al. found that aiming for 
a systolic blood pressure of less than 120 mm Hg, 
as compared with a target of less than 140 mm Hg, 
reduced the rate of adverse cardiovascular events 
among patients at high risk for cardiovascular 
events who did not have diabetes. However, it 
remains important to evaluate the effects of in-
tensive blood-pressure lowering on cognition.
Fuster1 designated heart–brain interaction as 
one of the top 10 cardiovascular concerns for the 
next decade. The relationship between hyperten-
sion and cognitive function is complex and not 
completely understood, and the results of clini-
cal trials of antihypertensive therapies on cogni-
tive function are not consistent. Some studies in-
dicate that lower blood pressure increases the risk 
of cognitive decline among elderly persons.2,3
The SPRINT Memory and Cognition in De-
creased Hypertension study and its magnetic reso-
nance imaging (MRI) substudy were designed to 
determine whether intensive versus standard 
blood-pressure lowering would affect cognitive 
decline and structural abnormalities in the brain.4 
However, the trial was discontinued early because 
of the benefit of the intervention with respect to 
reductions in cardiovascular disease. This trial 
was stopped before most of the 4-year data on 
cognitive function were collected. We hope that 
these remaining data can be collected and the 
question of the effects of intensive blood-pres-
sure lowering on cognition can be answered.
Hailong Dai, M.D., Ph.D. 
Xuefeng Guang, M.D.
Yan’an Affiliated Hospital 
Kunming, China 
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To the Editor: The article on SPRINT acknowl-
edges that the prevalence of hypertension is es-
pecially high among the elderly. However, the 
trial excluded patients with dementia, those who 
resided in assisted-living facilities or nursing 
homes, and those who were broadly specified to 
have a condition estimated to limit survival to 
less than 3 years. Therefore, the results are not 
generalizable to many older people with multiple 
coexisting conditions, frailty, and disability. This 
is especially disappointing because observational 
studies have shown that, paradoxically, mortality 
may be increased among older people with frailty 
who have tightly controlled blood pressure.1
The systematic exclusion of older people with 
frailty and nursing-home residents who may be 
at greater risk for adverse events and death be-
cause of tight blood-pressure control is regret-
table. This exclusion risks misapplication of the 
otherwise robust trial findings to populations 
who might not benefit and indeed may be 
harmed.
Oliver Todd, M.B., B.S. 
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To the Editor: Wright et al. conclude that 
among patients at high risk for cardiovascular 
events who did not have diabetes, the most ap-
propriate systolic blood-pressure target was less 
than 120 mm Hg. Among the secondary out-
comes, heart failure, death from cardiovascular 
causes, and death from any cause were signifi-
cantly lower in the intensive-treatment group 
than in the standard-treatment group.
There were obviously important differences 
between the intensive-treatment group and the 
standard-treatment group with respect to the 
proportion of patients who received antihyper-
tensive medications from each individual drug 
class. Several of these classes (in particular, 
angiotensin-converting–enzyme inhibitors,1 beta-
blockers,2 and aldosterone-receptor blockers3) 
have previously been shown to lead to signifi-
cant reductions in fatal and nonfatal cardiovas-
cular events among patients with heart failure or 
left ventricular dysfunction. The proportions of 
patients who received each of these three classes 
were significantly higher in the intensive-treat-
ment group than in the standard-treatment group. 
In the Discussion section of the article, the 
authors do not consider that this higher use of 
medications from beneficial drug classes could 
at least in part explain the magnitude of the 
benefit, even independent of the magnitude of 
blood-pressure lowering.
Luc A. Pierard, M.D., Ph.D.
University of Liege Hospital 
Liege, Belgium 
lpierard@ chu . ulg . ac . be
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To the Editor: In their editorial accompanying 
the article by Wright et al., Perkovic and Rodgers1 
state that “labeling trials as ‘positive’ or ‘nega-
tive’ is seductive but ultimately counterproduc-
tive; it is more helpful to look at the totality of 
available data.” On the basis of this principle, 
they compare SPRINT and the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial.
In the few outcomes presented (stroke, myo-
cardial infarction, heart failure, and the primary 
outcome), the test for interaction for SPRINT 
and ACCORD was not significant; this indicated 
similar effects in the two trials. However, analy-
ses of the most important outcomes in SPRINT, 
death and cardiovascular death, reveal a differ-
ent story. The test for interaction was significant 
for death (P for interaction = 0.02) and cardiovas-
cular death (P for interaction = 0.003), and the 
pooled analyses from these trials show no dif-
ferences in the risk of death (relative risk, 0.88; 
95% CI, 0.62 to 1.23; I2 statistic, 80.4%) or car-
diovascular death (relative risk, 0.77; 95% CI, 
0.43 to 1.39; I2 statistic, 79.1%) with the use of 
intensive blood-pressure control versus standard 
blood-pressure control.
These findings make any extrapolation of the 
SPRINT results to an ACCORD-like cohort of 
patients with diabetes inappropriate. Thus, the 
analysis of Perkovic and Rodgers does not allevi-
ate concerns that a blood pressure that is too 
low in a patient with diabetes and hypertension 
may increase the risk of cardiovascular events.2,3
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New York University School of Medicine 
New York, NY 
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The authors reply: Pfeffer asks how often anti-
hypertensive medications were discontinued in 
asymptomatic participants in the standard-treat-
ment group who had a systolic blood pressure of 
less than 130 mm Hg or less than 135 mm Hg. 
Antihypertensive therapy in the standard-treat-
ment group often required adjustment; 87% of 
participants required at least one reduction in the 
dose of medication to maintain systolic blood 
pressure in the range of 135 to 139 mm Hg. With-
drawal of medication was required in less than 
7.5% of participants. Such adjustments, although 
not standard in clinical practice, were required to 
adequately test the SPRINT hypothesis.
Vipler et al. suggest that stopping the SPRINT 
intervention early might have caused bias in the 
estimated intervention effect. All trial events were 
scrutinized by an independent data and safety 
monitoring board, and as shown in Figure S3 in 
the Supplementary Appendix (available with the 
full text of the article at NEJM.org), the intensive-
treatment group exceeded the predetermined 
stopping boundary on two consecutive occasions, 
the second time by a substantial margin. The 
sequential boundary used is known to produce 
less early stopping bias, and estimates from trials 
such as SPRINT, with a large number of events, 
are known to be less biased by early stopping. 
Before publication of our article, we computed 
an alternative estimate of the intervention effect, 
the median unbiased estimate.1 This estimate 
indicated that our inferences were unaffected by 
an early stopping bias.
Muskiet et al. ask whether certain subgroups 
of patients may be at greater risk for adverse 
events with a systolic blood pressure of less than 
120 mm Hg. Detailed safety and quality-of-life 
monitoring were conducted in our trial. The 
health outcomes in older patients and other sub-
groups are important questions.
McCormick et al. question whether sufficient 
attention has been paid to the technique of blood-
pressure measurement in SPRINT. Measurement 
of blood pressure in the trial followed recom-
mended procedures more closely than is typical 
in clinical practice. More attention should be 
paid to recommended techniques of blood-pres-
sure measurement in clinical settings. In response 
to Dai and Guang: analyses of data on cognitive 
function and results of MRI are under way.
Todd and Clegg express concern that residents 
of nursing homes and patients with dementia 
were excluded. We had difficulty obtaining in-
formed consent in the latter group. SPRINT did 
include an older population with diverse levels of 
fitness, and approximately 28% of the partici-
pants were classified as frail.2 The SPRINT find-
ings according to the level of frailty in this 
population were recently reported.3
Pierard suggests that differences in drug use 
according to treatment group in the trial may 
have influenced the results. The distribution of 
antihypertensive drug classes was similar be-
tween the randomized groups, except for the 
10 to 20% greater use of each major class in the 
intensive-treatment group. Previous studies com-
paring the effect of antihypertensive drug classes 
have shown little difference with respect to over-
all cardiovascular outcomes distinct from lower-
ing blood pressure, except in patients with pro-
teinuric nephropathy, coronary heart disease, or 
heart failure.4,5 Patients with heart failure were 
excluded, and appropriate drug therapy was rec-
ommended according to the protocol for other 
indications, regardless of the effect on systolic 
blood-pressure targets.
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Case Western Reserve University 
Cleveland, OH 
jackson . wright@ case . edu
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The editorialists reply: In reply to Bangalore 
et al.: in SPRINT and the ACCORD trial, we noted 
similar results with respect to cause-specific out-
comes (stroke, coronary disease, and heart fail-
ure). Since the degree of benefit varies across 
these outcomes and the proportions of the events 
in the composite outcomes (including death from 
cardiovascular causes and death from any cause) 
are different across trials, differences in compos-
ite outcomes are expected. In the ACCORD trial, 
more events were coronary, so composite out-
comes were less sensitive to blood pressure.
We suggest three causes of undue concern re-
garding blood-pressure lowering in diabetes. First, 
there is an overemphasis on individual trials or 
patient subgroups. We recommended consider-
ation of all randomized evidence, which shows no 
heterogeneity in cause-specific outcome effects in 
patients with or without diabetes and that blood-
pressure lowering above and below 140 mm Hg 
reduces cardiovascular events.1 A second cause is 
J-shaped curve associations from nonrandom-
ized analyses; these are inconsistent with ran-
domized trials1,2 and hence due to confounding. 
Third, meta-analyses3 can obscure the benefits 
of established blood-pressure-lowering regimens 
by giving undue weight to trials of dual renin-
angiotensin blockade. Dual renin-angiotensin 
blockade, which is now contraindicated because 
of specific harms, achieves minimal blood-
pressure reduction. Hence, trials of this therapy 
should play little or no role in considerations of 
the benefits of blood-pressure lowering in pa-
tients with diabetes or those with a systolic 
blood pressure below 140 mm Hg.
The totality of randomized evidence indicates 
that lower blood-pressure targets benefit people 
with diabetes and people without diabetes. Our 
focus should move to implementation.
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Corrections to Report of a Trial of Burch Colposuspension
To the Editor: On the basis of a report of an 
investigator who was using the public data set to 
replicate our reported data, we identified a cod-
ing error related to the urinary stress test used 
in our trial. We report corrections related to our 
original research article (April 13, 2006, issue).1
The overall conclusions of the trial remain 
supported by the corrected percentages, which 
are as follows: 3 months after surgery, 33.6% of 
the women in the Burch group and 57.4% of the 
women in the control group met one or more of 
the criteria for stress incontinence (P<0.001). A 
detailed correction notice in this issue of the 
Journal contains additional changes. The article 
has been corrected at NEJM.org. We wish to ac-
knowledge the data coordinating center at RTI 
International and the Pelvic Floor Disorders 
Network of the Eunice Kennedy Shriver National 
Institute of Child Health and Human Develop-
ment for correcting the data set and providing 
the analysis of the corrected data set.
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